Best Supplements to Take With PE-22-28

PE-22-28 Is Working Upstream, and That Changes What It Needs

Every antidepressant-adjacent compound has a different place in the chain. SSRIs work at the reuptake transporter, which is effectively the drain at the bottom of the serotonin pool. They keep serotonin in circulation longer by slowing how fast it gets cleared. PE-22-28 works at something else entirely: a potassium channel called TREK-1, which sits in hippocampal and cortical neurons and, when open, hyperpolarizes the cell and prevents it from firing.

When PE-22-28 binds TREK-1 and closes it, the neurons that were being suppressed become active again. The ones that matter most for mood are serotonergic neurons in the raphe nuclei, the clusters of cells in the brainstem that supply serotonin to the cortex and hippocampus. With TREK-1 blocked, those neurons disinhibit, fire more freely, and release more serotonin. Downstream, that increased serotonergic activity triggers a cascade involving BDNF, a protein that behaves like a growth factor for neurons. BDNF binds to its receptor on hippocampal cells and promotes synaptic remodeling and new neuron formation. PE-22-28 achieves this secondary effect in a way full-length BDNF cannot, because its truncated structure targets only the pro-survival receptor and avoids the receptor that, when activated by the full-length molecule, can trigger cell death instead.

This upstream mechanism is why the supplement picture for PE-22-28 looks different from what you would draw for a standard SSRI. An SSRI's job is to keep serotonin circulating. PE-22-28's job is to release it, which means the supply of serotonin matters more. If the brain is building less serotonin than it should, blocking TREK-1 has less to work with. Several B vitamins are rate-limiting for serotonin synthesis, and a shortfall in any of them creates exactly that ceiling.

There is a second, related problem. PE-22-28 targets the hippocampus specifically, a region that is unusually sensitive to nutritional status. Vitamin D deficiency, low iron, and insufficient B12 each produce a depressive and cognitive symptom profile that sits directly on top of the outcomes this compound is trying to improve. None of those deficiencies are corrected by TREK-1 inhibition. They have to be addressed separately, before the compound's effect can be read clearly. Running PE-22-28 on a depleted nutritional baseline is not just suboptimal; it makes evaluation genuinely impossible, because the compound and the deficiency produce the same symptom picture and only one of them responds to the peptide.

The Supplements That Matter Most on PE-22-28

There are no dose numbers on this page. The right amount of each of these depends on your specific protocol, your baseline bloodwork, and what else you are already taking. A flat number printed here would be wrong for most individuals reading it. The MyPeptidePal app resolves the amounts using your actual inputs.

The Membrane PE-22-28 Works Through

Omega-3 DHA

TREK-1 belongs to a category of ion channels called mechanosensitive channels, meaning their behavior responds to physical properties of the cell membrane rather than just to chemical signals arriving at a receptor. One of the physical properties that matters most is membrane fluidity, which is substantially determined by the fatty acid composition of the phospholipid bilayer the channel sits inside. DHA, the long-chain omega-3 fatty acid concentrated in neuronal membranes, is one of the primary determinants of that fluidity.

This makes DHA a genuine structural support for PE-22-28's mechanism rather than a generic brain-health recommendation. The lipid environment shapes how TREK-1 responds to binding, and DHA is what that environment is built from.

The double-duty case for omega-3s here is strong. EPA, DHA's companion fatty acid, has accumulated a meaningful body of controlled trial evidence for depression specifically, acting through anti-inflammatory pathways that are entirely separate from TREK-1. Neuroinflammation in the hippocampus actively counteracts neurogenesis, so reducing it extends the benefit of PE-22-28's downstream neuroplastic effect rather than merely adding to it through a different route. Both fatty acids also support the BDNF signaling pathway that PE-22-28 activates secondarily at the TrkB receptor.

The clinical evidence for EPA in depression is real and includes randomized controlled trials. The connection between DHA's membrane role and TREK-1 function is mechanistically well-grounded but has not been directly tested as a PE-22-28 pairing in human trials. Both are worth taking seriously for different reasons.

Correct These Before You Blame the Peptide

Vitamin B12

Vitamin B12 is required for two things that matter here. First, it maintains the myelin sheath around neurons, the fatty insulating layer that allows electrical signals to travel efficiently. Second, it feeds the methylation cycle, a set of chemical reactions the body uses to produce neurotransmitters and regulate gene expression in neural tissue. A B12 deficiency produces fatigue, cognitive slowing, low mood, and what is sometimes described as brain fog. That symptom picture is clinically identical to the target window PE-22-28 is aimed at.

Running PE-22-28 on a background of low B12 does not produce a partial result. It produces an uninterpretable one. The compound could be working and the deficiency could be masking it entirely, or both could be contributing to the same symptom picture in ways that cannot be separated without correcting the nutritional state first.

B12 deficiency is more common than most people assume. Absorption declines with age, certain medications including metformin reduce it, and dietary intake is almost entirely from animal products, meaning people eating restricted diets are at particular risk. Checking serum B12 before starting the protocol is worth more than most of the other steps in this stack.

Folate

Folate, specifically in its active form as methylfolate, works alongside B12 in the methylation cycle. Where folate becomes most directly relevant to PE-22-28 is through homocysteine. When the methylation cycle runs poorly due to folate or B12 insufficiency, homocysteine accumulates in the blood and in brain tissue. Elevated homocysteine is neurotoxic, and the tissue it damages most is hippocampal, which is precisely the region PE-22-28 is trying to remodel through neurogenesis.

The form matters here. Folic acid, the synthetic version found in most standard supplements and fortified foods, requires a conversion step that a significant fraction of people cannot complete efficiently due to a common genetic variant affecting the relevant enzyme. Methylfolate bypasses that conversion entirely and is the more reliable choice for this application.

Vitamin B6

B6 is where the B-vitamin story for PE-22-28 becomes most mechanistically direct. In its active form as pyridoxal-5-phosphate, B6 is the essential cofactor for the enzyme that converts 5-HTP into serotonin. That enzyme, called aromatic L-amino acid decarboxylase, simply cannot run without it. PE-22-28's mechanism depends on disinhibiting serotonergic neurons so they can fire and release serotonin. If the synthesis step immediately upstream is bottlenecked by inadequate B6, those neurons fire into a smaller supply.

This is the strongest single piece of mechanistic reasoning in the entire supplement picture for PE-22-28: the compound's primary target is serotonin release, and B6 directly limits serotonin production.

B6 also has a second job here. It is one of the more consistently studied anti-nausea supplements in the general literature, with controlled trial support in pregnancy-related nausea contexts. That evidence does not translate directly to PE-22-28's transient adjustment-phase nausea, but the mechanism is general enough to be relevant, and it makes B6 a double-duty pick: supporting the serotonin pathway and easing the compound's most common early side effect with a single supplement.

Vitamin D3

Vitamin D is less a serotonin-pathway supplement and more a confounder-removal one for PE-22-28. Deficiency is independently associated with increased depression risk through mechanisms that have nothing to do with TREK-1, including effects on inflammation, calcium signaling, and gene expression in brain tissue. Vitamin D receptors are expressed throughout the hippocampus, and vitamin D regulates BDNF expression in hippocampal cells, which overlaps directly with PE-22-28's downstream neuroplasticity mechanism.

The practical consequence is that a person running PE-22-28 with genuinely low vitamin D is carrying a competing depressive burden that the peptide cannot address. Correcting vitamin D status does not make PE-22-28 work better in any direct sense; it removes a separate reason the compound might look weaker than it actually is.

Vitamin D deficiency is genuinely widespread, particularly in northern latitudes, indoor-dominant lifestyles, and in individuals with darker skin tones. It is the most common correctable nutritional confounder for mood outcomes and is worth checking before attributing a suboptimal PE-22-28 response to the compound itself.

One practical note: vitamin D cannot activate to its usable form without adequate magnesium. The kidney requires magnesium to run the enzyme that converts vitamin D to its active hormone form. Co-administering magnesium is not optional here; it is what makes the vitamin D supplementation actually work. Vitamin K2 taken alongside it helps direct calcium appropriately as levels rise.

Iron

Iron earns its slot in this stack through two separate routes. The direct route: iron deficiency creates a fatigue and cognitive impairment picture that overlaps entirely with what PE-22-28 is being used to address. Low ferritin, even when hemoglobin is still in the normal range, is associated with depression, difficulty concentrating, and reduced motivation. A person running PE-22-28 with undetected low ferritin will struggle to separate the compound's effects from the nutritional deficit.

The indirect route: iron is a cofactor for the enzyme that converts vitamin D to its active form. Low iron suppresses vitamin D activation even when vitamin D levels appear adequate on a standard test, which means iron deficiency silently undermines the vitamin D correction described above.

Iron is the one supplement in this stack that should not be taken without bloodwork first. Ferritin is the marker that matters, not hemoglobin. Hemoglobin can stay normal while ferritin is depleted, and the symptoms appear before the hemoglobin falls. Supplementing iron without confirming deficiency carries real risks; elevated iron is harmful in its own right, and symptoms alone cannot reveal status. When ferritin is confirmed low, bioavailable forms are substantially gentler on the stomach than older iron salt preparations and are the practical first choice.

What Eases the Adjustment Phase

Magnesium Glycinate

PE-22-28's most commonly reported side effect is mild nausea during the first several days of use, accompanied in some individuals by a sense of overstimulation or heightened nervous-system sensitivity. Magnesium glycinate addresses the overstimulation component specifically.

Magnesium acts as a natural regulator of neuronal excitability. It physically occupies the pore of the NMDA receptor, a receptor involved in learning and memory, when the neuron is at rest, preventing unnecessary firing. As neuronal activity increases during PE-22-28's disinhibition of serotonergic pathways, adequate magnesium helps maintain the balance between excitatory and inhibitory signaling. People running neurologically active compounds on a background of low magnesium often find the stimulatory quality sharper and less comfortable than it would otherwise be.

Magnesium glycinate is the recommended form here because the glycinate version has high bioavailability and does not cause the loose stools that come with magnesium oxide or magnesium citrate at meaningful doses. Taking it in the evening suits most people and aligns with its calming properties.

This is a double-duty supplement across this stack. Beyond easing adjustment-phase overstimulation, magnesium is a required cofactor for serotonin synthesis and for vitamin D activation, both of which are covered in the sections above. One supplement, three supporting functions.

Amplifying the Calm-Focus Outcome

L-Theanine

L-theanine is an amino acid found naturally in tea leaves. Its notable property is that it promotes alpha-wave brain activity, the pattern associated with relaxed alertness, without causing sedation. It reduces anxious arousal and the subjective experience of mental tension, but it does not slow thinking or blunt focus the way a sedative would.

L-theanine does not share PE-22-28's mechanism. It does not touch TREK-1, does not affect serotonin synthesis, and does not modulate BDNF. What it does is target the calm-focus outcome through a completely different pathway, which makes it a genuine synergist rather than a redundant addition to the stack.

The specific value during a PE-22-28 protocol is that some users experience an adjustment period during the first week characterized by a mild stimulatory quality, heightened alertness, or a slightly restless edge before the anxiolytic and mood-supporting effects fully establish themselves. L-theanine can buffer that window without interfering with the compound's neuroplastic effects and without the risks that come from serotonergic supplements.

The anxiety-reducing properties of L-theanine at standard doses have support from controlled human trials, making it one of the more clinically grounded supplements in this stack for its stated purpose, even though the specific pairing with PE-22-28 has not been formally studied.

One note worth carrying: at standard amounts the serotonergic contribution from theanine is negligible and is not a concern. Exceptionally large amounts, well above what any standard protocol would use, may add minimally to serotonergic tone, but standard doses are well inside safe territory here.

Cautions and Interactions

Serotonergic Medications: A Hard Stop

The most important interaction associated with PE-22-28 is with serotonergic medications, and it is not a nuance. PE-22-28 works by increasing serotonin availability through upstream disinhibition of serotonergic neurons. SSRIs block serotonin reuptake downstream at the transporter. MAOIs block the enzyme that breaks serotonin down. SNRIs combine serotonin reuptake inhibition with norepinephrine effects. Any of these combined with PE-22-28 risks stacking serotonergic effects to a degree that can produce serotonin syndrome, a medical emergency characterized by agitation, elevated heart rate, high blood pressure, tremor, hyperthermia, and in severe cases seizures.

MAOIs carry the highest risk of this combination and represent an absolute contraindication. SSRIs and SNRIs carry serious risk. These are not combinations to manage with careful monitoring; they are combinations to avoid entirely without direct physician evaluation by someone who understands both mechanisms.

This interaction has no formal human pharmacokinetic study behind it because PE-22-28 has no completed Phase 1 human safety trial. The risk assessment is mechanism-derived and has a sound theoretical basis. The absence of a confirmed human case does not make the combination safe.

Acetylcholinesterase Inhibitors

PE-22-28 potentiates cholinergic signaling as part of its mechanism profile. Acetylcholinesterase inhibitors, used for cognitive decline and Alzheimer's disease, raise acetylcholine levels by blocking the enzyme that breaks it down. When these two mechanisms combine, the result is excessive cholinergic tone, which produces nausea, slowed heart rate, muscle weakness, and excessive GI activity. Avoid this combination without direct physician guidance.

Serotonergic Supplements

5-HTP directly raises the precursor load for serotonin synthesis. Combined with PE-22-28's upstream enhancement of serotonin release, this creates a theoretical risk of serotonin excess, particularly at higher 5-HTP doses. The combination is not an absolute contraindication at low amounts the way SSRI combinations are, but it warrants conservative introduction and attention to early signs of excess, including restlessness, rapid heart rate, or GI discomfort.

St. John's Wort has mild serotonin reuptake inhibiting properties. At therapeutic doses for mood support, the concern mirrors that of SSRIs in miniature: the mechanism stacks rather than complements, and the combination should be approached cautiously.

Cardiovascular Monitoring

TREK-1 channels are expressed in cardiac tissue as well as neuronal tissue. At research doses in animal models, PE-22-28 did not produce clinically significant heart rate changes, but a theoretical bradycardia risk exists. This becomes a practical concern when combined with beta-blockers, which lower heart rate through a different mechanism. Anyone taking beta-blockers and considering PE-22-28 should discuss the combination with their prescribing physician and monitor resting heart rate consistently.

High-Dose Choline Supplements

Alpha-GPC, CDP-choline, and similar choline-heavy supplements raise acetylcholine levels. At standard doses this is not a concern. At high doses combined with PE-22-28's cholinergic activity, the profile resembles that of acetylcholinesterase inhibitors at a lower intensity: nausea, headache, and a potential bradycardia contribution. Keep choline supplementation at moderate amounts if using it alongside this compound.

Frequently Asked Questions

How much of each supplement should I take with PE-22-28?

There are no dose numbers on this page, and that is intentional. The right amount of each supplement depends on your baseline bloodwork, your body weight, what else you are currently taking, and the specific protocol you are running. A flat number printed here would be accurate for the average of a population and wrong for most individuals within it. The MyPeptidePal app takes your actual inputs and works out the amounts that make sense for your situation.

Which blood markers should I check before starting PE-22-28?

The most useful baseline panel covers ferritin, 25-OH-D, serum B12, and homocysteine if available. Ferritin and vitamin D are the two most commonly low in the general population and the two most likely to create a symptom picture that overlaps with what the compound is being used to address. RBC magnesium, not serum magnesium, is the correct marker for assessing magnesium status, since serum magnesium is tightly regulated and rarely reflects true intracellular levels. Retesting after eight to twelve weeks of supplementation tells you whether the gaps are actually closing.

Can I take PE-22-28 if I am already on an antidepressant?

Not without a physician who understands the mechanism of both. PE-22-28 increases serotonin availability through TREK-1 channel inhibition, and the most commonly prescribed antidepressants, SSRIs and SNRIs, work by blocking serotonin reuptake. These two mechanisms stack rather than complement each other, and the combined effect risks serotonin syndrome. This is the most serious interaction associated with PE-22-28 and is not a matter of dose management or careful timing. It requires direct medical evaluation before any combination is attempted.

Do these supplements interfere with how PE-22-28 works?

For the supplements on this list, no. Omega-3s, B vitamins, vitamin D, magnesium, and L-theanine at standard doses do not interfere with TREK-1 inhibition and do not compete with PE-22-28's mechanism. The supplements to be cautious about are the ones that amplify serotonin through their own routes, specifically 5-HTP and St. John's Wort, where stacking effects are possible rather than competitive. Those are covered in the cautions section above.

Is PE-22-28's evidence base strong enough to justify running this stack?

PE-22-28 has no completed Phase 1 human safety trial, and no large randomized controlled trial has tested it in people. The mechanistic evidence for TREK-1 inhibition is well-established in preclinical research, and the downstream neuroplasticity effects have solid scientific grounding, but the human data is limited to anecdotal reports from self-experimentation contexts. The supplements in this stack, by contrast, have substantially stronger clinical backing for their individual roles: B vitamins and serotonin synthesis, vitamin D and mood, magnesium and neuronal function, EPA and depression. Running this stack is largely about not limiting the compound's potential with correctable deficiencies, regardless of what eventual human trial evidence for PE-22-28 specifically shows.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of PE-22-28 and the nutrients that support it in one place.